Importance of monitoring renal function in patients with cancer

Cancer Treatment Reviews

Volumn 38, Issue 3, 2012, Pages 235-240

  Aapro, Matti ^a   Launay Vacher, Vincent ^b  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antiresorptive agents; Cancer; Cancer therapy; Creatinine clearance; Renal impairment

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CISPLATIN; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; DIAZIQUONE; GADOLINIUM; GALLIUM NITRATE; IBANDRONIC ACID; IFOSFAMIDE; IODINATED CONTRAST MEDIUM; METHOTREXATE; MITHRAMYCIN; MITOMYCIN C; NITROSOUREA; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PENTOSTATIN; RADIOPHARMACEUTICAL AGENT; RECOMBINANT INTERLEUKIN 2; SEMUSTINE; SOMATOSTATIN DERIVATIVE; SORAFENIB; STREPTOZOCIN; SUNITINIB; ZOLEDRONIC ACID;

BODY MASS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC KIDNEY DISEASE; CLEARANCE; COCKCROFT GAULT EQUATION; COMORBIDITY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE EXACERBATION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MODIFICATION OF DIET IN RENAL DISEASE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEOPLASM; NEPHROTOXICITY; PATIENT MONITORING; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SOLID TUMOR; URINALYSIS;

AGED; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; CREATININE; GUIDELINES AS TOPIC; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; NEOPLASMS; RENAL INSUFFICIENCY; RISK FACTORS; URINE SPECIMEN COLLECTION;

EID: 84857655227     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.05.001     Document Type: Review

References (59)

1. Lichtman S.M., Villani G. Chemotherapy in the elderly: pharmacologic considerations. Cancer Control 2000, 7:548-556.
2. Sahni V., Choudhury D., Ahmed Z. Chemotherapy-associated renal dysfunction. Nat Rev Nephrol 2009, 5:450-462.
3. Launay-Vacher V., Oudard S., Janus N., et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency and Anticancer Medications (IRMA) study. Cancer 2007, 110:1376-1384.
4. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139:137-147.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39:S1-S266.
6. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
7. Launay-Vacher V., Etessami R., Janus N., et al. Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung 2009, 187:69-74.
8. Launay-Vacher V., Gligorov J., Le Tourneau C., et al. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 2010, 124:745-753.
9. Launay-Vacher V., Ayllon J., Janus N., et al. Drug management of prostate cancer: prevalence and consequences of renal insufficiency. Clin Genitourin Cancer 2009, 7:E83-E89.
10. Janus N., Oudard S., Beuzeboc P., et al. Prevalence of renal insufficiency in cancer patients: Data from the IRMA-2 study. J Clin Oncol 2009, 27(Suppl):497s. [abstract 9559].
11. Dimopoulos M.A., Terpos E., Chanan-Khan A., et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol 2010, 28:4976-4984.
12. Tsakiris D.J., Stel V.S., Finne P., et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol Dial Transplant 2010, 25:1200-1206.
13. Stevens L.A., Li S., Wang C., et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2010, 55:S23-33.
14. Launay-Vacher V., Spano J.P., Janus N., et al. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol 2009, 70:124-133.
15. Launay-Vacher V., Izzedine H., Rey J.B., et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit 2004, 10:CR209-12.
16. Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol 2010, 30:548-556.
17. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002;94:2766-92.
18. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997, 80:1273-1283.
19. Singer M. Management of comorbid diabetes and cancer. Oncology (Williston Park) 2007;21:26-37; discussion follows.
20. Aapro M., Abrahamsson P.A., Body J.J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008, 19:420-432.
21. Ailabouni W., Eknoyan G. Nonsteroidal anti-inflammatory drugs and acute renal failure in the elderly. A risk-benefit assessment. Drugs Aging 1996, 9:341-351.
22. Andrew E., Berg K.J. Nephrotoxic effects of X-ray contrast media. J Toxicol Clin Toxicol 2004, 42:325-332.
23. Barone R., Borson-Chazot F., Valkema R., et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005, 46:99S-106S.
24. Breitz H., Wendt R., Stabin M., Bouchet L., Wessels B. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP. Cancer Biother Radiopharm 2003, 18:225-230.
25. Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009, 6:465-477.
26. Giralt S., Bensinger W., Goodman M., et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 2003, 102:2684-2691.
27. Hasebroock K.M., Serkova N.J. Toxicity of MRI and CT contrast agents. Expert Opin Drug Metab Toxicol 2009, 5:403-416.
28. Huerta C., Castellsague J., Varas-Lorenzo C., Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005, 45:531-539.
29. Kintzel P.E. Anticancer drug-induced kidney disorders. Drug Saf 2001, 24:19-38.
30. Lambert B., Cybulla M., Weiner S.M., et al. Renal toxicity after radionuclide therapy. Radiat Res 2004, 161:607-611.
31. Launay-Vacher V., Rey J.B., Isnard-Bagnis C., Deray G., Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 2008, 61:903-909.
32. Perazella M.A. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf 2008, 3:67-75.
33. Perazella M.A. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 2009, 4:461-469.
34. Vogelzang N.J. Nephrotoxicity from chemotherapy: prevention and management. Oncology (Williston Park) 1991, 5:97-102. 5; discussion follows.
35. Launay-Vacher V., Karie S., Fau J.B., Izzedine H., Deray G. Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. J Pain 2005, 6:137-148.
36. Launay-Vacher V., Chatelut E., Lichtman S.M., Wildiers H., Steer C., Aapro M. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007, 18:1314-1321.
37. Kelly R.J., Billemont B., Rixe O. Renal toxicity of targeted therapies. Target Oncol 2009, 4:121-133.
38. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007, 96:1788-1795.
39. Launay-Vacher V., Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 2009, 20:81-82.
40. Li Y.F., Fu S., Hu W., et al. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 2007, 17:739-763.
41. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
42. Body J.J., Coleman R., Clezardin P., Ripamonti C., Rizzoli R., Aapro M. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 2007, 43:852-858.
43. Zometa prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.
44. Van Poznak C.H., Temin S., Yee G.C., et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011, 29:1221-1227.
45. Bondronat® 2mg and 6mg concentrate for solution for infusion. Summary of product characteristics. Roche Diagnostics GmbH and Roche Products Limited. Available at: ; Published June 25, 1996, Revised April 2, 2010 [accessed 21.04.11]. http://www.medicines.org.uk.
46. Launay-Vacher V, Janus N, Karie S, Deray G. Letter. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 2007;17:1340-1; author reply follows.
47. Pamidronate prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.
48. Bondronat® film-coated tablets 50mg/2mg/2mL, 6mg/6mL concentrate solution for infusion. Professional Information Swiss Drug Compendium. Roche Pharma (Schweiz) AG. ; Published April 2009. [accessed 21.04.11.]. http://www.kompendium.ch.
49. Kim H.H., Shin H.S., Kwak H.J., et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. FASEB J 2003, 17:2163-2165.
50. Theill L.E., Boyle W.J., Penninger J.M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002, 20:795-823.
51. Xgeva prescribing information. Thousand Oaks, CA: Amgen Inc.; 2010.
52. Fizazi K., Carducci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
53. Henry D.H., Costa L., Goldwasser F., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29:1125-1132.
54. Stopeck A.T., Lipton A., Body J.J., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
55. Lipton A, Siena S, Rader M, et al. Comparison of denosumab versus zoledronic acid for treatment of bone metastases in advanced cancer patients: an integrated analysis of 3 pivotal trials. Presented at: 35th ESMO Congress; October 8-12, 2010; Milan, Italy [abstract 1249].
56. Klejna K., Naumnik B., Gasowska K., Mysliwiec M. OPG/RANK/RANKL signaling system and its significance in nephrology. Folia Histochem Cytobiol 2009, 47:199-206.
57. Raggi P., Giachelli C., Bellasi A. Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis. Nat Clin Pract Cardiovasc Med 2007, 4:26-33.
58. Kartsogiannis V., Zhou H., Horwood N.J., et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 1999, 25:525-534.
59. Lichtman S.M., Wildiers H., Launay-Vacher V., Steer C., Chatelut E., Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007, 43:14-34.